Collegium Pharmaceutical sells prescription medicines for ADHD and pain in the United States. COLL reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell).
Prices, price targets and earnings estimates for COLL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in COLL in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COLL is in one of them and how their past COLL trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Collegium Pharmaceutical
Collegium Pharmaceutical is a biopharmaceutical company based in Stoughton, Massachusetts. It sells prescription medicines in the United States for attention deficit hyperactivity disorder and for moderate to severe pain. Its products include Jornay PM for ADHD, Belbuca, Xtampza ER and the Nucynta products for pain, and Symproic for constipation caused by opioid use. Its customers are patients who receive these medicines through prescriptions written by doctors.
